Almirall, S.A. (BME:ALM)

Market Cap	2.46B +15.6%
Revenue (ttm)	1.11B +12.5%
Net Income	46.15M +354.9%
EPS	0.22 +354.9%
Shares Out	214.79M
PE Ratio	53.04
Forward PE	28.24
Dividend	0.19 (1.66%)
Ex-Dividend Date	May 15, 2025

Volume	102,931
Average Volume	181,257
Open	11.52
Previous Close	11.44
Day's Range	11.36 - 11.72
52-Week Range	8.65 - 13.98
Beta	0.15
RSI	32.22
Earnings Date	Feb 23, 2026

About Almirall

Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism, anti-infective for systemic use, cardiovascular system, dermatological, genito urinary system and sex hormones, immunostimulants, metabolism, musculo-skeletal sys...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1943
• Employees: 2,108
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: ALM

Financial Performance

In 2025, Almirall's revenue was 1.11 billion, an increase of 12.51% compared to the previous year's 990.63 million. Earnings were 46.15 million, an increase of 354.85%.